Pharmaceutical giant Roche bought health tech startup Flatiron Health for $1.9 billion in 2018 to expand its reach into real-world evidence and accelerate its development of cancer medicines. However, the Swiss pharma company is considering divesting Flatiron Health, the Financial Times reported, citing people familiar with the matter. Roche is now working with Citigroup to assess options for Flatiron, including divesting the business or selling part of the company to a partner that could help run the business, the FT report said.
Read the full article: Roche Considering Sale of Cancer Data Startup Flatiron Health: Report //
Source: https://www.fiercehealthcare.com/health-tech/roche-considering-sale-cancer-data-startup-flatiron-health-report